What targeted therapies are available for Prostate Cancer

Targeted Therapies for Prostate Cancer

Targeted therapies are treatments designed to attack specific genetic mutations or proteins found in your cancer cells. Unlike traditional chemotherapy that affects many cells, targeted therapies work like "smart bombs"—they focus on particular vulnerabilities in your cancer. Let me walk you through the main categories available for prostate cancer.

BIOMARKER-TARGETED THERAPIES (PARP Inhibitors)

According to the NCCN Guidelines, these are among the most important targeted options for advanced prostate cancer, especially if you have specific genetic mutations.

How they work: PARP inhibitors block an enzyme called PARP that helps cancer cells repair damaged DNA. When PARP is blocked, cancer cells can't fix their DNA damage and die.

Who benefits: About 1 in 4 patients with metastatic hormone-resistant prostate cancer have mutations in genes like BRCA1, BRCA2, or other DNA-repair genes. If you have these mutations, PARP inhibitors may be effective.

Available PARP inhibitors include:

• Olaparib (Lynparza) - Can be used with abiraterone for BRCA-mutated patients, or alone after other hormone therapies fail
• Rucaparib (Rubraca) - For BRCA-mutated patients who've had both hormone therapy and chemotherapy
• Talazoparib (Talzenna) - Combined with enzalutamide for BRCA or DNA-repair gene mutations
• Niraparib with abiraterone (Akeega) - A newer combination for BRCA-mutated patients

Key point: These only work if you have the specific genetic mutations. Genetic testing is essential to determine if you're a candidate.

---

RADIOPHARMACEUTICALS (Radioactive Particle Therapy)

These are newer, innovative treatments that deliver radiation directly to cancer cells.

Lutetium-177 (Pluvicto)

How it works: This treatment uses a radioactive particle that attaches to PSMA (prostate-specific membrane antigen)—a protein on the surface of prostate cancer cells. The radiation then kills the cancer cells from inside.

When it's used: After you've had both hormone therapy and chemotherapy (docetaxel or cabazitaxel)

Important requirement: You need a PSMA-PET scan first to confirm your cancer cells have enough PSMA for this treatment to work

Treatment schedule: Intravenous infusion once every 6 weeks for up to 6 doses

Response rates: According to Dr. [removed] Sartor's expert webinar on radiopharmaceuticals, about one-third of patients have excellent responses, one-third have minimal response, and one-third fall in the middle.

Radium-223 (Xofigo)

How it works: This radioactive treatment collects in bones and delivers radiation to kill cancer cells there

When it's used: For prostate cancer that has spread mainly to bones but NOT to internal organs

Treatment schedule: One injection per month for 6 months

Important: Usually combined with bone-targeted therapy (denosumab or zoledronic acid) to prevent fractures

---

ANDROGEN RECEPTOR (AR) DEGRADERS

These are newer drugs that work differently than traditional hormone-blocking drugs. Instead of just blocking the androgen receptor, they actually destroy it.

Examples in development:

• ProTac and other degraders like RV-766 are showing promise for castrate-resistant prostate cancer

These represent the next generation of hormone-targeted therapy and may be options as they become more widely available.

---

IMMUNOTHERAPY

According to the NCCN Guidelines, immunotherapy is used selectively for specific patient populations:

Pembrolizumab (Keytruda)

• Used for patients with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H)
• These are genetic markers that indicate your immune system may respond well to this treatment
• Typically used after hormone therapy and chemotherapy have been tried

Sipuleucel-T (Provenge)

• An immunotherapy that trains your own immune cells to fight cancer
• Used for patients with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer
• Works best when cancer burden is lower and immune system is stronger
• NOT recommended if cancer has spread to internal organs (liver)

---

COMBINATION APPROACHES

According to NCCN Guidelines and expert webinars, newer treatment strategies combine multiple targeted approaches:

• PARP inhibitors + Androgen Receptor inhibitors (e.g., olaparib + abiraterone) - blocks DNA repair AND hormone signaling simultaneously
• Radiopharmaceuticals + Immunotherapy - combining lutetium-177 with pembrolizumab in clinical trials
• Tyrosine kinase inhibitors + Immunotherapy - targeting specific mutations while boosting immune response

---

EMERGING TARGETS BEING RESEARCHED

Dr. [removed] webinar highlights many targets currently in clinical trials:

• PSMA-targeted therapies (antibody drug conjugates, bispecific antibodies)
• B7-H3, STEAP1, STEAP2 (cell surface proteins)
• TROP2, NECTIN4 (targets for antibody-drug conjugates)
• VEGF pathway inhibitors (for angiogenesis—cutting off blood supply to tumors)
• DLL3-targeted therapies (especially for neuroendocrine prostate cancer)
• WNT pathway inhibitors
• AKT inhibitors

---

IMPORTANT QUESTIONS TO ASK YOUR ONCOLOGIST

1. Have I had genetic testing (both germline and tumor testing) to identify mutations like BRCA1/BRCA2 or mismatch repair deficiency?

2. Do I have PSMA-positive disease? (This determines if radiopharmaceuticals like Pluvicto are options)

3. What is my current disease stage and burden? (This affects which targeted therapies are appropriate)

4. Are there clinical trials available for combination approaches or newer targeted therapies?

5. Which targeted therapy do you recommend for MY specific situation, and what are the expected benefits and side effects?

6. Should I get additional biomarker testing like circulating tumor DNA (ctDNA) or tumor microenvironment analysis to guide treatment selection?

---

KEY TAKEAWAY

Targeted therapies for prostate cancer are increasingly personalized based on your specific genetic mutations and biomarkers. The NCCN Guidelines emphasize that genetic and molecular testing is essential—about 20% of patients will have actionable mutations that point to specific targeted treatments. Even if you don't have a specific mutation, newer radiopharmaceuticals and immunotherapies offer additional options depending on your disease characteristics.

Your oncologist will determine which targeted approach is most appropriate based on your complete clinical picture, previous treatments, and specific biomarkers.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.